Molecular Modelling of Human DT-Diaphorase For Enzyme-Directed Bioreductive Drug Design
- 1 August 2000
- journal article
- research article
- Published by Taylor & Francis in Molecular Simulation
- Vol. 24 (4-6), 209-214
- https://doi.org/10.1080/08927020008022371
Abstract
The enzyme DT-Diaphorase (NAD(P)H:quinone acceptor oxidoreductase, EC 1.6.99.2.; DTD) has been recognised as a good target for enzyme-directed bioreductive drug development. This is due to elevated levels of enzyme activity in several human tumour types and its role in the bioreductive activation of several quinone-based anti-cancer drugs. Bioreductive drugs are designed to exploit one of the features of solid tumours, namely tumour hypoxia. However, selectivity of bioreductive drugs is not only governed by oxygen levels, but also by the levels of the enzymes catalysing bioreductive activation, leading to the concept of “enzyme-directed bioreductive drug development” introduced by Workman and Walton in 1990. This concept requires the identification of tumours within a patient that have elevated levels of enzyme activity (enzyme profiling) and treating the patient with drugs activated by such enzymes. DTD has been singled out as a particularly good candidate for such targeting. In order to rationalise the design of drugs to target DTD, molecular modelling techniques have been employed. The human DTD three-dimensional structure has been modelled with homology to the known rat DTD structure (about 85% identity) and the model refined using energy minimisation. Drug-binding orientations have been determined and molecular dynamics simulations performed. Using data from a series of quinone based compounds with a broad range of substrate specificity we examine drug-enzyme interactions and suggest how DTD substrate specificity might be further optimised.Keywords
This publication has 7 references indexed in Scilit:
- Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-β-en-α-ol (EO9) by human DT-diaphoraseBiochemical Pharmacology, 1996
- The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction.Proceedings of the National Academy of Sciences, 1995
- Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolismBiochemical Pharmacology, 1995
- Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinonesInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Enzyme-Directed Bioreductive Drug DevelopmentPublished by Springer Nature ,1990
- A computational procedure for determining energetically favorable binding sites on biologically important macromoleculesJournal of Medicinal Chemistry, 1985
- CHARMM: A program for macromolecular energy, minimization, and dynamics calculationsJournal of Computational Chemistry, 1983